MyStart Health Review

MyStart Health — Provider Profile

Overview

MyStart Health is a direct-to-consumer telehealth platform focused on affordable GLP-1 weight loss prescriptions. The company entered the compounded semaglutide market in 2024, offering budget pricing with an asynchronous consultation model. Limited public information is available about the company's founding team, headquarters, or clinical governance structure.

April 2026 context: MyStart Health offers compounded GLP-1 medications. Orforglipron (Eli Lilly oral GLP-1) is not yet FDA-approved — PDUFA date April 10, 2026. Medicare GLP-1 Bridge coverage for obesity is pending. Compounded semaglutide supply is declining under FDA enforcement pressure.

As a newer entrant to the telehealth GLP-1 market, MyStart Health competes primarily on price. The platform follows the standard playbook of async medical questionnaire, provider review, and direct-to-door medication shipping.

Medications Offered

• Compounded semaglutide (injectable) — GLP-1 receptor agonist via compounding pharmacy
• Compounded tirzepatide (injectable) — Dual GIP/GLP-1 agonist, subject to FDA enforcement

Pricing

• Compounded semaglutide — From $99/month
• Compounded tirzepatide — From $149/month (availability varies)
• Consultation included — No separate consultation fee

Pros

• Budget-friendly compounded GLP-1 pricing
• All-inclusive pricing with no hidden fees
• Fast async onboarding process
• No subscription commitment required

Cons

• Compounded medications only — no brand-name options
• Compounded GLP-1 supply faces active FDA enforcement pressure
• Limited company transparency — no founding year or leadership
• No video consultations available
• No lab testing included
• No nutrition coaching or wraparound care
• Very limited online review history